Cohort profile update: the main and new findings from the sami-trop chagas cohort

• Autor(a) principal: Claudia di Lorenzooliveira
• Data de Publicação: 2021
• Outros Autores: Lewis f. Buss, Desiree Sant?ana Haikal, Edecio Cunha Neto, Antonio Luiz Pinho Ribeiro, Ester Cerdeira Sabino, Clareci Silva Cardoso, Nayara Ragi Baldoni, Larissa Natany, Ariela Mota Ferreira, Lea Campos de Oliveira, Maria do Carmo Pereira Nunes, Nayara Dornela Quintino, Ana Luiza Bierrenbach
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: http://hdl.handle.net/1843/62855
• topic: Doença de Chagas; Medicina

The SaMi-Trop project is a cohort study conducted in 21 municipalities of endemic areas of Chagas disease, including 1,959 patients with chronic Chagas cardiomyopathy. In this article we updated the results of the project, adding information from the second cohort visit. Trypanosoma cruzi-seropositive patients were enrolled from the primary care Telehealth service in Minas Gerais State, Brazil. The eligibility criterium for the second visit was the participation in the baseline evaluation. Of 1,959 participants at the baseline assessment, 1,585 (79.9%) returned after two years for the second evaluation. The mortality rate was 6.7%, but varied from 0.9% to 18.2% when it was stratified by certain clinical characteristics. A lower age-adjusted NT-Pro-BNP level (less than 300) and a prior benznidazole treatment were associated with lower mortality. There was an improvement in most quality of life domain scores. Participants have also reported fewer signs and symptoms and greater use of medication. The second follow-up visit will be complete in Oct 2021.